Cancer patients keep access to promising drug in safety Follow-Up study

NCT ID NCT02632994

First seen Oct 31, 2025 · Last updated May 09, 2026 · Updated 21 times

Summary

This study offers continued access to an investigational cancer drug for patients who were already benefiting from it in a previous study. The main goal is to monitor long-term safety. Participants must have completed an earlier Lilly study and still be getting benefit from the drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fort Wayne Oncology & Hematology

    AVAILABLE

    Fort Wayne, Indiana, 46804, United States

    Contact Phone: •••-•••-••••

    Contact

  • Sarah Cannon Cancer Center

    AVAILABLE

    Nashville, Tennessee, 37203, United States

    Contact Phone: •••-•••-••••

    Contact

  • UCLA Medical Center

    AVAILABLE

    Torrance, California, 90505, United States

    Contact Phone: •••-•••-••••

    Contact

Conditions

Explore the condition pages connected to this study.